Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Drugs in Development, 2021

November 2021 | 76 pages | ID: N438A8BCDA63EN
Global Markets Direct

Abstracts

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Drugs in Development, 2021

SUMMARY

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Neuronal Acetylcholine Receptor Subunit Alpha 7 - Drugs In Development, 2021, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Neuronal acetylcholine receptor subunit alpha-7 is a protein encoded by the CHRNA7 gene. After binding to acetylcholine it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 4 and 7 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal and Oncology which include indications Alzheimer's Disease, Cognitive Impairment Associated With Schizophrenia (CIAS), Schizophrenia, Traumatic Brain Injury, Anxiety Disorders, Cognitive Impairment, Pain, Parkinson's Disease, Bipolar Disorder (Manic Depression), Cognitive Disorders, Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), Dementia Associated With Alzheimer's Disease, Ischemic Stroke, Major Depressive Disorder, Mild Cognitive Impairment, Neuropathic Pain (Neuralgia), Panic Disorders, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder (SAD/Social Phobia) and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)
• The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics and enlists all their major and minor projects
• The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Overview
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Companies Involved in Therapeutics Development
180 Life Corp
AlphaCognition Inc
AstraZeneca Plc
Bionomics Ltd
Bristol-Myers Squibb Co
DanPET AB
Epigen Biosciences Inc
Lupin Ltd
Merck & Co Inc
Neuro Bio Ltd
SK Biopharmaceuticals Co Ltd
Vanda Pharmaceuticals Inc
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Drug Profiles
ALPHA-1062 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVL-3288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVL-8168 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-0328 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-910731 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-375 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPGN-1137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LL-00066471 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NBP-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NS-12877 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKL-20540 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize CHRNA7 for Ulcerative Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize CHRNA7 for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VQW-765 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Dormant Products
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Discontinued Products
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Product Development Milestones
Featured News & Press Releases
Nov 01, 2021: Bionomics Receives FDA clearance of IND for evaluation of BNC210 in a phase 2 social anxiety disorder PREVAIL study
Nov 01, 2021: Bionomics gets FDA approval for trial of social anxiety disorder treatment
Sep 20, 2021: Bionomics prepares BNC210 for start of phase 2 acute treatment of social anxiety disorder trial
Sep 09, 2021: Alpha Cognition to Webcast Live on ALPHA-1062 at Life Sciences Investor Forum September 16th
Sep 07, 2021: Alpha Cognition announces the acceptance of its US FDA investigational new drug application (IND) for lead candidate, ALPHA-1062 for mild to moderate Alzheimer’s Disease
Jul 08, 2021: Novamind selected as research site for Bionomics' PTSD clinical trial
Jul 06, 2021: Bionomics initiates phase 2b ATTUNE study of BNC210 in PTSD
May 10, 2021: Bionomics expanding BNC210 for acute treatment of social anxiety disorder in addition to phase 2b trial for post traumatic stress disorder
Apr 30, 2021: Agilex Biolabs congratulates Bionomics on BNC210 PK results
Apr 27, 2021: Alpha Cognition announces Ms. Colleen Johns as SVP, product development further strengthening the ALPHA-1062 drug commercialization team
Apr 12, 2021: Alpha Cognition announces Mr. Michael McFadden as chief executive officer and realignment of leadership team for next stage of alpha-1062 drug development
Feb 22, 2021: Positive BNC210 7-Day dosing pharmacokinetic study exceeds blood exposure projected for phase 2b PTSD trial
Jan 18, 2021: Publication of positive BNC210 phase 2a data in generalised anxiety disorder patients
Jan 07, 2021: Bionomics presenting at virtual H.C. Wainwright Bioconnect 2021 conference
Jan 04, 2021: Bionomics initiates 7-day dosing pharmacokinetic study of BNC210 tablet formulation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by 180 Life Corp, 2021
Pipeline by AlphaCognition Inc, 2021
Pipeline by AstraZeneca Plc, 2021
Pipeline by Bionomics Ltd, 2021
Pipeline by Bristol-Myers Squibb Co, 2021
Pipeline by DanPET AB, 2021
Pipeline by Epigen Biosciences Inc, 2021
Pipeline by Lupin Ltd, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by Neuro Bio Ltd, 2021
Pipeline by SK Biopharmaceuticals Co Ltd, 2021
Pipeline by Vanda Pharmaceuticals Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021